Komori
Susmed (4263) · InitiativeAdvanced

Joint Development with Niigata University of a Therapeutic App for Persistent Postural-Perceptual Dizziness

First written in FY2024. 2 of 3 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026-H1.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025-H1 – FY2026-H12024: 120242025: 120252026: 12026
Same theme, other companies
Joint Development with Niigata University of a Therapeutic App for Persistent Postural-Perceptual DizzinessA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AdvancedAnnual report

    「In addition, development is progressing smoothly, including the completion of a clinical research study for the therapeutic app for persistent postural-perceptual dizziness being jointly developed with Niigata University, a national university corporation.」

    The Company completed the clinical research study for the therapeutic app for persistent postural-perceptual dizziness being jointly developed with Niigata University.
  2. FY2025-H1AdvancedAnnual report

    「In addition, development is progressing smoothly, including the commencement of subject enrollment in a clinical research study for the therapeutic app for persistent postural-perceptual dizziness being jointly developed with Niigata University, a national university corporation.」

    The Company commenced subject enrollment in a clinical research study for the therapeutic app for persistent postural-perceptual dizziness being jointly developed with Niigata University.
  3. FY2024First statedAnnual report

    「The Company presented at the annual meeting and academic conference of the Japanese Society of Otorhinolaryngology-Head and Neck Surgery on the therapeutic app for persistent postural-perceptual dizziness being jointly developed with Niigata University, a national university corporation, and added the app to its development pipeline.」

    Following a presentation at an academic conference, the Company added to its development pipeline the therapeutic app for persistent postural-perceptual dizziness being jointly developed with Niigata University.
Moved together

"Medium- to long-term incentives for directors through restricted stock compensation" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1Medium- to long-term incentives for directors through restricted stock compensation2×
  3. 2Stabilizing Platform Revenue by Increasing the Number of Companies That Continue to Use the Platform2×
  4. 3Use of a clinical trial system implementing blockchain technology2×
  5. 4Joint development and sales agreement with Asuka Pharmaceutical for a therapeutic app in the obstetrics and gynecology field2×
  6. 5Provision of a General-Purpose Clinical Trial System and a Machine-Learning-Based Automated Analysis System2×
  7. 6Tokyo Stock Exchange Mothers listing and financing through a public offering2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Susmed's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Joint Development with Niigata University of a Therapeutic App for Persistent Postural-Perceptual Dizziness | SUSMED,Inc. (4263) | Komori